ITT Institute of Tumours of Tuscany (logo)
Advanced search

AOU Senese

Pub Med

pubmed

Immunoterapia Oncologica - Ricerca Traslazionale

U.O.C. Immunoterapia Oncologica
Azienda Ospedaliera Universitaria Senese
Viale Bracci 16, 53100 Siena
Tel: 0577/586336
Fax: 0577/586303

Ricercatori associati:
Dr.ssa Maresa Altomonte
Dr.ssa Lucia Anzalone
Dr.ssa Luana Calabrò
Dr.ssa Ester Fonsatti
Dr. Massimo Guidoboni
Dr.ssa Antonia Anna Lettini
Dr. Hugues Nicolay
Dr.ssa Marianna Sabatino
Dr.ssa Francesca Semplici
Enzo Cortini
Erika Falisi

Progetti Specifici

  • 8.1.1.: "Identificazione mediante profilo genico di nuovi bersagli molecolari immunobiologici e farmacologici per la terapia del melanoma e del neuroblastoma".
    DATA INIZIO: 2003
    DATA FINE: 2006
  • 8.1.2.: "Immunobiologic and clinical activity of DNA hypomethylating agents in human cutaneous melanoma".
    DATA INIZIO: 2005
    DATA FINE: 2007
  • 8.1.3.: "Sviluppo di strategie terapeutiche di bioimmunoterapia nel mesotelioma maligno".
    DATA INIZIO: 2005
    DATA FINE: 2008
  • 8.1.4.: "Studio della risposta T cellulare indotta dalla vaccinoterapia con anticorpi anti-idiotipo nel melanoma avanzato e nel carcinoma del colon-retto".
    DATA INIZIO: 2005
    DATA FINE: 2007
  • 8.1.5.: "Progetto Dipartimentale per lo sviluppo della Banca Biologica di Tessuti".
    In fase di attivazione.
  • 8.1.6.: "Profili d'espressione genica e proteica in cellule emopoietiche normali e maligne a fenotipo immaturo".
    DATA INIZIO: 2005
    DATA FINE: 2007
  • 8.1.7.: "Ruolo dell' Endoglina (CD105) quale indicatore di angiogenesi nelle neoplasie solide, marcatore di malattia nelle emopatie maligne, e target antigenico per protocolli di immunoterapia umorale".
    DATA INIZIO: 1998
    DATA FINE: 2008
  • 8.1.8.: "Valutazione genetica dell'effetto della instabilità cromosomica sul programma trascrizionale delle cellule tumorali".
    DATA INIZIO: 2005
    DATA FINE: 2008
  • 8.1.9.: "Metilazione del DNA, profilo immunologico, telomerasi/telomeri nel melanoma cutaneo umano: studi in vitro ed in vivo ed implicazioni terapeutiche".
    DATA INIZIO: 2006
    DATA FINE: 2007

Grants

  • Progetto 8.1.1.:
    Compagnia di San Paolo – Torino:
    "Identificazione mediante profilo genico di nuovi bersagli molecolari immunobiologici e farmacologici per la terapia del melanoma e del neuroblastoma". (2003-2006)
  • Progetto 8.1.2.:
    Associazione Italiana per la Ricerca sul Cancro:
    "Biologic and immunotherapeutic potential of DNA hypomethylation in human cutaneous melanoma". (2000-2002); "Nuove strategie terapeutiche di combinazione: ipometilazione del DNA e bioimmunoterapia". (2002); "Immunobiologic and clinical activity of DNA hypomethylating agents in human cutaneous melanoma". (2005-2007)
  • Progetto 8.1.3.:
    Fondazione Buzzi:
    "Sviluppo di strategie terapeutiche di Bioimmunoterapia nel Mesotelioma Maligno". (2005-2008)
  • Progetto 8.1.6.:
    Ministero della Sanità - Progetti di Ricerca Finalizzata:
    "Profili d'espressione genica e proteica in cellule emopoietiche normali e maligne a fenotipo immaturo". (2005-2007)
  • Progetto 8.1.7.:
    Ministero della Sanità, Progetti di Ricerca Finalizzata:
    "Ruolo dell' Endoglina (CD105) quale indicatore di angiogenesi nelle neoplasie solide, marcatore di malattia nelle emopatie maligne, e target antigenico per protocolli di immunoterapia umorale". (1998-2001)
  • Progetto 8.1.8.:
    Società di Esecutori di Pie Disposizioni in Siena:
    "Valutazione genetica dell'effetto della instabilità cromosomica sul programma trascrizionale delle cellule tumorali". (2005-2006)
  • Progetto 8.1.9.:
    Progetto Piano di Ateneo per la Ricerca (PAR):
    "Metilazione del DNA, profilo immunologico, telomerasi/telomeri nel melanoma cutaneo umano: studi in vitro ed in vivo ed implicazioni terapeutiche". (2006-2007)

Collaborazioni

  • Progetto 8.1.1.: Unità di Immunoterapia dei Tumori Umani, Istituto Nazionale per lo Studio e Cura dei Tumori, I.R.C.C.S., Milano; MOLMED, Milano.
  • Progetto 8.1.2.: Unità di Bioimmunoterapia Oncologica, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano; Dept. of Medical Oncology, Thomas Jefferson University, Philadelphia, USA; Skin Cancer Unit, University Hospital, Mannheim, Germany; Dept. of Medicine, University of Halle, Germany.
  • Progetto 8.1.3.: Unità di Bioimmunoterapia Oncologica, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA; Gruppo Italiano per lo Studio e la Terapia del Mesotelioma Maligno.
  • Progetto 8.1.4.: Unità di Bioimmunoterapia Oncologica, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano; Dept. of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA; Wistar Institute, Philadelphia, USA; Free University, Berlin, Germany

Pubblicazioni (dal 2001)

  1. Gasparollo A, Coral S, Ciullo M, Prisco A, Nardi G, Cattarossi I, Altomonte M, Guardiola J, and Maio M. Unbalanced expression of HLA-A and -B antigens: a common feature of non-hemopoietic malignancies. Int J Cancer, 91:500-507, 2001.
  2. Maio M, Altomonte M, Calabrò, and Fonsatti E. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies. Front Biosci, 6:d776-784, 2001.
  3. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra M.R, Coral S, Natali P.G, and Maio M. Endoglin: an accessory component of the TGF-binding receptor-complex with prognostic, diagnostic and bioimmunotherapeutic potential in human malignancies. J Cell Physiol, 188:1-7, 2001.
  4. Giordano GG, Muto M, Sigalotti L, Maio M.Cancer therapies: basic and clinical perspectives in brain, prostate, and lung tumors: Naples, September, 24-27, 2000. J Cell Physiol, 188:274-280, 2001.
  5. Maio M, Altomonte M, and Fonsatti E. Critical Commentary to: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. Women’s Oncol Rev, 1:175-177, 2001
  6. Maio M, Altomonte M, and Fonsatti E. Critical Commentary to: Immunological consolidation of ovarian carcinoma recurrences with monoclonal antibody ACA125: Immune responses and survival in palliative treatment. Women’s Oncol Rev,1:363-364, 2001.
  7. Maio M, Fonsatti E, Calabrò L, Sigalotti L, Coral S, Altomonte M. Vaccini, terapia genica e cancro. In: Genetica e Cancro. Una sfida aperta fra i tumori e la scienza. Collana: Le nuove tessere. CUEN, Napoli, pp. 89-123, 2001
  8. Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G Giorgi G, Francini G. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (molgramostim) and hr-IL-2: results from a phase Ib clinical trial. Eur J Cancer, 37:892-902; 2001.
  9. Correale P, Cusi MG, Sabatino M, Micheli L, Pozzessere D, Nencini C, Valensin PE, Petrioli R, Giorgi G, Zurbriggen R, Gluck R, Francini G. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer, 37:2097-2103; 2001.
  10. Correale P, Micheli L, Del Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer, 85:1722-1730; 2001.
  11. Correale P, Sabatino M, Cusi MG, Micheli L, Nencini C, Pozzessere D, Petrioli R, Aquino A, De Vecchis L, Turriziani M, Prete SP, Sanguedolce R, Rausa L, Giorgi G, Francini G. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate syntase. J Chemother, 13:519-526; 2001.
  12. Dolcetti R, Guidoboni M, Viel A, Boiocchi M. Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level., Cancer Epidemiol. Biomark Prev, 10:917-923, 2001.
  13. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macri E, Lanza G, Boiocchi M, Dolcetti R. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol, 159:297-304, 2001.
  14. Ponzoni M, Fumagalli L, Rossi G, Freschi M, Re A, Vigano MG, Guidoboni M, Dolcetti R, McKenna RW, Facchetti F. Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma. Mod Pathos;15:1273-1278, 2002.
  15. Petrioli R, Fiaschi AI, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A, Salvestrini F, and Francini G. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer, 87:720-725; 2002.
  16. Francini G, Petrioli R, Messinese S, Pozzessere D, Marsili S, Correale P, Sabatino M, Fiaschi AI. Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. Cancer Chemother Pharmacol, 50:271-276; 2002.
  17. Giordano GG, Sigalotti L, Maio M. Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies. J Cell Physiol, 191:362-365, 2002.
  18. McClay EF, Maio M. Introduction: Melanoma: American and European perspectives on diagnosis and treatment. Semin Oncol, 29:306-307, 2002.
  19. De Nardo C, Fonsatti E, Sigalotti L, Calabrò L, Colizzi F, Cortini E, Coral S, Altomonte M, Maio M. A recombinant transmembrane CD59 (CD59-TM) confers complement resistences to GPI-anchored protein defective melanoma cells. J. Cell Physiol, 190:200-206, 2002.
  20. Musolino C, Calabrò L, Bellomo G, Martello F, Loteta B, Pezzano C, Rizzo V, Alonci A. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol, 69:159-163, 2002.
  21. Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Vianale G, Martini F, Tognon M, Jungbluth A, Cebon J, Maraskovsky E, Mutti L, Maio M. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer, 86:979-982, 2002.
  22. Calabrò L, Alonci A, Bellomo G, D’Angelo A, Di Giacomo V, Musolino C. ”Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report.” Hematology, 2002,
  23. Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother, 25:16-26, 2002.
  24. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G. Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer. Immunol. Immunother, 51:9-14, 2002.
  25. Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F., Vianale G, Martini F, Tognon M, Jungbluth A, Cebon J, Maraskovsky E, Mutti L, and Maio M. Cancer Testis Antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Brit J Cancer, 86: 979-982, 2002.
  26. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, and Maio M. 5-AZA-2’-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Can Res, 8:2690-2695, 2002.
  27. Altomonte M, and Maio M. European approach to antibody-based immunotherapy of melanoma. Semin. Oncol, 29:471-478, 2002.
  28. Musolino C, Calabrò L, Bellomo G, Cincotta M, Di Giacomo V, Pezzano C, Loteta B, Rizzo V, Guglielmo S, Alonci A. Lipid profile in hematologic neoplasms. Recenti Prog Med, 93:298-301, 2002.
  29. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol, 2041:4169-80, 2002.
  30. Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P. High affinity HLA-A(*)02.01 peptides from parathyroid-hormone related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol, 169:4840-4849, 2002.
  31. Lettini AA Meggio F, Pinna LA, Oliviero S. CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation. Oncogene, 21:3978-3987, 2002.
  32. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Ceciarini F, Marsili S, Correale P, Fiaschi AI, Voltolini L, Gotti G, Francini G. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer, 39:85-89, 2003.
  33. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Di Palma T, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology, 64:300-305, 2003.
  34. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Rovello F, Pinto E, Francini G, Giorni G. Gemcitabine increases systemic 5-fluorouracile exposure in advanced cancer patients. Eur J Cancer, 39:1547-1551, 2003.
  35. Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G, Francini G. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer, 89:239-242, 2003.
  36. Calabrò L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Altomonte M, Musolino C, and Maio M. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol, 194:171-175, 2003.
  37. Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, Cortini E, Colizzi F, Fenzi G, Altomonte M, Pinchera A, and Vitale M. Analysis of Cancer-Testis Antigens in sporadic medullary tyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocr Metab, 88:748-754, 2003.
  38. Fonsatti E, Altomonte M, Arslan P, Maio M. Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets, 4:291-296, 2003.
  39. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M, Lubbert M, Wijermans PW, Jones PA, Hellstrom-Lindberg E. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood, 101:4644-4646, 2003.
  40. Altomonte M, Fonsatti E, Visintin A, Maio M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene, 22:6564-6569, 2003.
  41. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 22:6557-6563, 2003.
  42. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene, 22: 6484-6488, 2003.
  43. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets, 3:427-32, 2003.
  44. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer, 20:430-431, 2003.
  45. Coppola G, Castaldo P, Miraglia Del Giudice E, Bellini G, Galasso F, Soldovieri MV, Anzalone L, Sferro C, Annunziato L, Pascotto A, Taglialatela M. “A novel KCNQ2 K+ channel mutation in benign neonatal convulsions and centrotemporal spikes”. Neurology, 61:131-134, 2003.
  46. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res, 64:9167-9171, 2004.
  47. Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M. Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res, 10:8142-6, 2004.
  48. Altomonte M, Visintin A, Tecce R, Leonardi A, Calabrò L, Fonsatti E, Pucillo C, Maio M. Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. J Cell Physiol, 200:272-276, 2004.
  49. Fonsatti E, Di Giacomo AM, Maio M. Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? J Transl Med, 2:21, 2004.
  50. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med, 2:18, 2004.
  51. Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M, Mazzaferro V, Coppa J, Srivastava PK, Parmiani G. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother, 53:227-233, 2004.
  52. Zancai P, Cariati R, Quaia M, Guidoboni M, Rizzo S, Boiocchi M, Dolcetti R. Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. Int J Oncol; 25:345-355, 2004.
  53. Riccioni R, Rossini A, Calabrò L, Diverio D, Pasquini L, Lococo F, Peschle C, Testa U. Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. Leuk Lymphoma, 45:1511-1517, 2004.
  54. Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology, 63:321-326, 2004
  55. Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabrò L. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol, 72:416-419, 2004.
  56. Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G.UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer; 90:306-9, 2004.
  57. Ferreri AJM, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischauer K, Caggiari L, Lettini AA, Dal Cin E, Ieri R, Freschi M, Villa E, Boiocchi M, Dolcetti R. Evidence for association between Chlamydia Psittaci and ocular adnexal lymphomas. J Natl Cancer Inst, 96:586-594, 2004.
  58. Guidoboni M, M Ponzoni M, L Caggiari L, Lettini AA, L Vago L, De Re V, Gloghini A, Zancai P, Carbone A, Baiocchi M, Dolcetti R. Latent membrane protein-1 deletion mutants accumulate in Reed-Sternberg cells of HIV-related Hodgkin’s lymphoma. J Virol, 79:2643-2649, 2005.
  59. Ferreri AJM, Ponzoni M, Guidoboni M, De Conciliis M, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell’Oro S, Dogliosi C, Villa E, Boiocchi M, Dolcett R. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol, 23:5067-5073, 2005.
  60. Maio M. I vaccini nell’immunoterapia dei tumori. Suppl. Tumori, 3:S26-27, 2004.
  61. Calabrò L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol, 202:474-477, 2005.
  62. Petrioli R, Sabatino M, Roviello F, Marrelli D, Nastri G, Marsili S, Correale P, Pozzessere D, Messinese S, De Martino A, Tani F, Marzocca G, Lorenzi M, Civitelli S, Tanzini G, Pinto E, Francini G. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. Hepatogastroenterology, 52:1626-1630, 2005.
  63. Correale P, Marsili S, Sabatino M, Montagnani F, Giorgi G, Francini G. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncol Rep, 13:751-756, 2005.
  64. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C, De Paoli P. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother, 55:23-30, 2006.
  65. Zancai P, Dal Col J, Piccinin S, Guidoboni M, Cariati R, Rizzo S, Boiocchi M, Maestro R, Dolcetti R. Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene; 24:2483-2494, 2005.
  66. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res;65:587-595, 2005.
  67. Ferreri AJ, Ponzoni M, Martinella G, Muti G, Guidoboni M, Dolcetti R, Doglioni C. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica, 90:1578-1579, 2005.
  68. Wang E, Voiculescu S, Le Poole IC, El-Gamil M, Li X, Sabatino M, Robbins PF, Nickoloff BJ, Marincola FM.Clonal Persistence and Evolution During a Decade of Recurrent Melanoma.
    J Invest Dermatol, 2006 Feb 9; [Epub ahead of print].
  69. Coppola S, Narciso L, Feccia T, Bonci D, Calabrò L, Morsilli O, Gabbianelli M, De Maria R, Testa U, Peschle C.Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death Differ, 13:61-74, 2006.
  70. Palange P, Testa U, Huertas A, Calabro L, Antonucci R, Petrucci E, Pelosi E, Pasquini L, Satta A, Morici G, Vignola MA, Bonsignore MR.Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J, 27:529-541, 2006.
  71. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, Lettini AA, Sacchetti F, Dolcetti R, Doglioni C, Ponzoni M.Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol, 2006 Mar 8; [Epub ahead of print].
  72. Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R.Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives.
    Clin Lymphoma Myeloma, 6:289-300, 2006.
  73. Ferreri AJ, Ponzoni M, Viale E, Guidoboni M, Conciliis CD, Resti AG, Politi L, Lettini AA, Sacchetti F, Dognini G, Dolcetti R, Doglioni C.Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications.
    Hematol Oncol, 24:33-37, 2006.
  74. Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. J Cell Physiol, 207:58-66, 2006.
  75. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchiano A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Florio AD, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother, 2005 Oct 8; 1-11 [Epub ahead of print]
  76. Maio M, Altomonte M, Fonsatti E. Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res, 69:781-783, 2006.